Myelobromol farmakokinetikai vizsgálata csontvelo- Átültetés elotti kondicionálást követoen

Translated title of the contribution: Pharmacokinetics of myelobromol in conditioning regimen before bone marrow transplantation

Pap Éva, Erdélyi Tóth Valéria, Barta Anikó, Bátai Árpád, Lengyel Lilla, Torbágyi Éva, K. Pálóczi, Kelemen Endre

Research output: Contribution to journalArticle

Abstract

Objectives: Dibromomannitol (DBM) has been used, in conditioning regimens for BMT since 1982 in Hungary. Population pharmacokinetic analysis of the drug was carried out in 30 patients undergoing bone marrow transplantation, as well as in 24 patients after single oral dose of 500 mg (test dose) pre-transplant. The pharmacokinetic data of the single oral dose was compared with the pharmacokinetic and pharmacodynamic results of the repeated doses in the conditioning regimen. Methods: DBM was assayed in plasma using the previously described HPLC method (13). Results: A significant proportion of the variability of pharmacokinetic parameters could be attributed to sex, and also to age in women. The occurrence of acut GVHD was highly correlated with the increased AUC. ft has been demonstrated that peak concentrations lower than 25 μM in male patients receiving test dose predispose to relapse. Conclusions: Therapeutic monitoring should produce improved results in patients undergoing BMT by both decreasing treatment-related toxicity and improving antitumor activity.

Original languageHungarian
Pages (from-to)35-40
Number of pages6
JournalMagyar Onkologia
Volume43
Issue number1
Publication statusPublished - 1999

Fingerprint

Mitobronitol
Bone Marrow Transplantation
Pharmacokinetics
Hungary
Area Under Curve
High Pressure Liquid Chromatography
Transplants
Recurrence
Therapeutics
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Oncology

Cite this

Éva, P., Valéria, E. T., Anikó, B., Árpád, B., Lilla, L., Éva, T., ... Endre, K. (1999). Myelobromol farmakokinetikai vizsgálata csontvelo- Átültetés elotti kondicionálást követoen. Magyar Onkologia, 43(1), 35-40.

Myelobromol farmakokinetikai vizsgálata csontvelo- Átültetés elotti kondicionálást követoen. / Éva, Pap; Valéria, Erdélyi Tóth; Anikó, Barta; Árpád, Bátai; Lilla, Lengyel; Éva, Torbágyi; Pálóczi, K.; Endre, Kelemen.

In: Magyar Onkologia, Vol. 43, No. 1, 1999, p. 35-40.

Research output: Contribution to journalArticle

Éva, P, Valéria, ET, Anikó, B, Árpád, B, Lilla, L, Éva, T, Pálóczi, K & Endre, K 1999, 'Myelobromol farmakokinetikai vizsgálata csontvelo- Átültetés elotti kondicionálást követoen', Magyar Onkologia, vol. 43, no. 1, pp. 35-40.
Éva P, Valéria ET, Anikó B, Árpád B, Lilla L, Éva T et al. Myelobromol farmakokinetikai vizsgálata csontvelo- Átültetés elotti kondicionálást követoen. Magyar Onkologia. 1999;43(1):35-40.
Éva, Pap ; Valéria, Erdélyi Tóth ; Anikó, Barta ; Árpád, Bátai ; Lilla, Lengyel ; Éva, Torbágyi ; Pálóczi, K. ; Endre, Kelemen. / Myelobromol farmakokinetikai vizsgálata csontvelo- Átültetés elotti kondicionálást követoen. In: Magyar Onkologia. 1999 ; Vol. 43, No. 1. pp. 35-40.
@article{504b8f7dc39b450b98f272957a49047e,
title = "Myelobromol farmakokinetikai vizsg{\'a}lata csontvelo- {\'A}t{\"u}ltet{\'e}s elotti kondicion{\'a}l{\'a}st k{\"o}vetoen",
abstract = "Objectives: Dibromomannitol (DBM) has been used, in conditioning regimens for BMT since 1982 in Hungary. Population pharmacokinetic analysis of the drug was carried out in 30 patients undergoing bone marrow transplantation, as well as in 24 patients after single oral dose of 500 mg (test dose) pre-transplant. The pharmacokinetic data of the single oral dose was compared with the pharmacokinetic and pharmacodynamic results of the repeated doses in the conditioning regimen. Methods: DBM was assayed in plasma using the previously described HPLC method (13). Results: A significant proportion of the variability of pharmacokinetic parameters could be attributed to sex, and also to age in women. The occurrence of acut GVHD was highly correlated with the increased AUC. ft has been demonstrated that peak concentrations lower than 25 μM in male patients receiving test dose predispose to relapse. Conclusions: Therapeutic monitoring should produce improved results in patients undergoing BMT by both decreasing treatment-related toxicity and improving antitumor activity.",
author = "Pap {\'E}va and Val{\'e}ria, {Erd{\'e}lyi T{\'o}th} and Barta Anik{\'o} and B{\'a}tai {\'A}rp{\'a}d and Lengyel Lilla and Torb{\'a}gyi {\'E}va and K. P{\'a}l{\'o}czi and Kelemen Endre",
year = "1999",
language = "Hungarian",
volume = "43",
pages = "35--40",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "1",

}

TY - JOUR

T1 - Myelobromol farmakokinetikai vizsgálata csontvelo- Átültetés elotti kondicionálást követoen

AU - Éva, Pap

AU - Valéria, Erdélyi Tóth

AU - Anikó, Barta

AU - Árpád, Bátai

AU - Lilla, Lengyel

AU - Éva, Torbágyi

AU - Pálóczi, K.

AU - Endre, Kelemen

PY - 1999

Y1 - 1999

N2 - Objectives: Dibromomannitol (DBM) has been used, in conditioning regimens for BMT since 1982 in Hungary. Population pharmacokinetic analysis of the drug was carried out in 30 patients undergoing bone marrow transplantation, as well as in 24 patients after single oral dose of 500 mg (test dose) pre-transplant. The pharmacokinetic data of the single oral dose was compared with the pharmacokinetic and pharmacodynamic results of the repeated doses in the conditioning regimen. Methods: DBM was assayed in plasma using the previously described HPLC method (13). Results: A significant proportion of the variability of pharmacokinetic parameters could be attributed to sex, and also to age in women. The occurrence of acut GVHD was highly correlated with the increased AUC. ft has been demonstrated that peak concentrations lower than 25 μM in male patients receiving test dose predispose to relapse. Conclusions: Therapeutic monitoring should produce improved results in patients undergoing BMT by both decreasing treatment-related toxicity and improving antitumor activity.

AB - Objectives: Dibromomannitol (DBM) has been used, in conditioning regimens for BMT since 1982 in Hungary. Population pharmacokinetic analysis of the drug was carried out in 30 patients undergoing bone marrow transplantation, as well as in 24 patients after single oral dose of 500 mg (test dose) pre-transplant. The pharmacokinetic data of the single oral dose was compared with the pharmacokinetic and pharmacodynamic results of the repeated doses in the conditioning regimen. Methods: DBM was assayed in plasma using the previously described HPLC method (13). Results: A significant proportion of the variability of pharmacokinetic parameters could be attributed to sex, and also to age in women. The occurrence of acut GVHD was highly correlated with the increased AUC. ft has been demonstrated that peak concentrations lower than 25 μM in male patients receiving test dose predispose to relapse. Conclusions: Therapeutic monitoring should produce improved results in patients undergoing BMT by both decreasing treatment-related toxicity and improving antitumor activity.

UR - http://www.scopus.com/inward/record.url?scp=84882953417&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882953417&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84882953417

VL - 43

SP - 35

EP - 40

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 1

ER -